Prostate Cancer - Results from #60

Comparison of Posttherapy 4- and 24-Hour [177Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate Cancer. November 1, 2024

Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [177Lu]Lu-PSMA-617. November 1, 2024

PSMA PET/CT Accuracy in Diagnosing Prostate Cancer Nodes Metastases. November 1, 2024

Adiposity and Muscle Strength in Men With Prostate Cancer and Cardiovascular Outcomes. November 1, 2024

Prostate-specific Antigen at 3 Months as a Predictor of Radiologic Progression-free Survival in Metastatic Hormone-sensitive Prostate Cancer Treated with Apalutamide: Analysis of 633 Patients in a Real-world Database. October 31, 2024

Incidence and mortality of prostate cancer in France from 2010 to 2021, using a real-life database (National Health Data System - SNDS) - the CaPCo Study. October 31, 2024

Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS-Meet-URO 26 Real-W October 31, 2024

Diagnostic utility of prostate health index density prior to MRI-ultrasound fusion targeted biopsy. October 31, 2024

A pilot study of AI-assisted reading of prostate MRI in Organized Prostate Cancer Testing. October 31, 2024

The Journey of Antibody-Drug Conjugates: Lessons Learned from 40 Years of Development October 30, 2024

Pelvic Lymph Node Dissection in Prostate Cancer: Update from a Randomized Clinical Trial of Limited Versus Extended Dissection. October 30, 2024

AI-derived Tumor Volume from Multiparametric MRI and Outcomes in Localized Prostate Cancer. October 30, 2024

Practice patterns and predictors of treatment intensification in patients with metastatic castration-sensitive prostate cancer. October 30, 2024

Identifying the best candidate for focal therapy: a comprehensive review. October 30, 2024

Germline DNA damage repair variants and prognosis of patients with high-risk or metastatic prostate cancer. October 30, 2024

Safety and Efficacy of Neoadjuvant Docetaxel and Radiotherapy in Localized High-Risk Prostate Cancer: Results From a Prospective Pilot Study. October 30, 2024

What's in a Name? Why Words Matter in Advanced Prostate Cancer. October 30, 2024

Inter-reader reliability and diagnostic accuracy of PI-RADS scoring between academic and community care networks: How wide is the gap? October 29, 2024

Evaluating Biparametric Versus Multiparametric Magnetic Resonance Imaging for Diagnosing Clinically Significant Prostate Cancer: An International, Paired, Noninferiority, Confirmatory Observer Study. October 29, 2024

The Association of Statin Use With Survival Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Androgen Receptor Targeted Therapies (ART). October 29, 2024

Page 4 of 1437